SCHEMBL10189795

SCHEMBL10189795

CCc1cc(-c2nn[nH]c2-c2ccc(C(F)(F)F)cc2)c(O)cc1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.36
HSP90AA1 P07900 3/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
MAPT P10636 2/20 0.35
KDM4E B2RXH2 1/20 0.35
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35
SNCA P37840 2/20 0.35
FRK P42685 1/20 0.35
CAMK2B Q13554 1/20 0.35
CAMK2G Q13555 1/20 0.35
CAMK2D Q13557 1/20 0.35
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
RXRG P48443 1/20 0.34
DHODH Q02127 1/20 0.34
TNIK Q9UKE5 1/20 0.34
HSP90AB1 P08238 1/20 0.34
MET P08581 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10189793 0.87 LTB4R (0.37) HSP90AA1MEN1KMT2AMAPTKDM4E
SCHEMBL10189697 0.86 TNIK (0.38) HSP90AA1MEN1KMT2AMAPTKDM4E
SCHEMBL411574 0.86 MEN1 (0.45) MEN1KMT2AMAPTKDM4ETDP1
SCHEMBL10189792 0.85 HSP90AA1 (0.39) HSP90AA1MEN1KMT2AMAPTKDM4E
SCHEMBL10189794 0.85 HSP90AA1 (0.36) HSP90AA1MEN1KMT2AMAPTKDM4E
SCHEMBL10189722 0.83 MEN1 (0.51) HSP90AA1MEN1KMT2AMAPTHSP90AB1
SCHEMBL412707 0.74 MEN1 (0.48) HSP90AA1MEN1KMT2AMAPTKDM4E
SCHEMBL12338740 0.72 MEN1 (0.54) HSP90AA1MEN1KMT2AMAPTKDM4E
SCHEMBL412493 0.72 MEN1 (0.47) HSP90AA1MEN1KMT2AMAPTKDM4E
SCHEMBL410619 0.71 MEN1 (0.56) HSP90AA1MEN1KMT2AMAPTHSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9175022-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2015-11-03 US disclosed
US-8501790-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-08-06 US disclosed
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 PIK3CA 808/4885HSP90AA1 289/4885MEN1 1571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.